Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sequenom, Aclaris, and Xenoport Making Waves Among Elite Healthcare Investors

Page 1 of 2

Three prominent healthcare-focused funds that we track at Insider Monkey submitted filings with the SEC today, disclosing new or bulked up positions in three different healthcare stocks. Given their focus and expertise on the healthcare sector, the stocks at the heart of these funds’ moves should be given consideration as potential investments. In this article we’ll find out what those stocks are and who is investing in them.

James Flynn Deerfield Management

Firstly, let’s check in on James Flynn’s (pictured) healthcare fund Deerfield Management, which filed today on biopharmaceutical company XenoPort Inc. (NASDAQ:XNPT). Deerfield’s filing revealed a 6.29 million-share position in Xenoport, representing 9.97% of its common shares. Deerfield is not the only fund we track that has made a move on XenoPort recently, as just last week, Steven Boyd’s Armistice Capital reported upping its holding to 2.6 million shares. Unlike Armistice however, which held 1.6 million shares on June 30, Deerfield’s position in the stock is a new one for the firm.

James E. Flynn
James E. Flynn
Deerfield Management

Both investors believe they have caught XenoPort Inc. (NASDAQ:XNPT) at the right price given its sharp decline in the middle of September. Its precipitous drop of over 37% during a span of four trading sessions beginning on September 14 followed the revelation that its psoriasis treatment XP23829 was causing frequent gastrointestinal-related side effects in testing, which led to nearly one-third of the trial subjects prematurely dropping out of the study. On the other hand however, the study did meet its primary endpoint, exhibiting efficacy for reducing lesions in psoriatic patients.

Follow Xenoport Inc (NASDAQ:XNPT)
Trade (NASDAQ:XNPT) Now!

Hedge funds in our database held 27.80% of XenoPort Inc. (NASDAQ:XNPT)’s shares on June 30, before the latest purchases, which would push the total to nearly 40% barring other as-yet-unreported moves. Thus, elite investors are quite bullish on the stock and the product candidates of the company. In addition to Boyd’s position, Julian Baker and Felix Baker’s Baker Bros. Advisors was another noteworthy shareholder of XenoPort’s as of June 30, owning 6.51 million shares.

A reader might question our decision to focus on the small-cap category, considering that it’s mostly the larger counterparts of these companies that head the portfolios of most hedge funds. The reason for our focus is simple. Our research has shown that in the period between 1999 and 2012 the top small-cap picks of hedge funds outperformed the broader market by nearly one percentage point per month, whereas the top overall picks (mostly large-caps) underperformed by seven basis points per month during the same period. Why pay high fees to own a glut of low-performing stocks when you can invest on your own in hedge funds’ best stock picks? Since its launch in August 2012, Insider Monkey’s small-cap strategy has outperformed the S&P 500 every year, returning 102% since then, nearly two-times greater returns than the S&P 500 (read the details here).

Check out the following page to get the lowdown on the other two healthcare filings of note, including one concerning a newly-public company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!